Labs conducting reproductive toxicity studies in animals use 90-day pre-breeding washouts for peptides with unknown teratogenic profiles, and BPC-157 remains in that category despite two decades of research use
The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Funds investments more than the market as a whole, to the extent that the Funds investments are concentrated in the securities and/or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector, market segment or asset class
and licensed by Lilly, orforglipron opens the door to a new generation of incretin-based therapies more accessible, manufacturable, and globally deployable
[5] The core regulatory point is one many patients do not realize: compounded drugs do not go through FDA premarket review for safety, quality, or effectiveness